MedTrace Logo

Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed Glioblastoma

NCT03055208 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-05-11

No results posted yet for this study

Summary

Gamma GBM is a single-arm phase II trial that prospectively measures the progression-free survival time after addition of an early gamma knife boost to areas of residual tumor to standard-of-care (surgery, chemo-radiotherapy, chemotherapy).

Conditions

Interventions

RADIATION

gamma knife radiosurgery (15 Gy to 50% isodose)

Radiosurgery with a gamma knife resembles the application of a precisely focused, high single dose of ionizing irradiation.

Sponsors & Collaborators

  • Universitätsmedizin Mannheim

    lead OTHER

Principal Investigators

  • Frank A Giordano, MD · University Medical Center Mannheim

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-08
Primary Completion
2020-03-30
Completion
2023-05-09

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03055208 on ClinicalTrials.gov